PL3474904T3 - Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb - Google Patents
Otrzymywanie przeciwciał monoklonalnych znakowanych 212pbInfo
- Publication number
- PL3474904T3 PL3474904T3 PL17732126.2T PL17732126T PL3474904T3 PL 3474904 T3 PL3474904 T3 PL 3474904T3 PL 17732126 T PL17732126 T PL 17732126T PL 3474904 T3 PL3474904 T3 PL 3474904T3
- Authority
- PL
- Poland
- Prior art keywords
- obtaining
- monoclonal antibodies
- labelled monoclonal
- labelled
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16176263 | 2016-06-24 | ||
| PCT/EP2017/065508 WO2017220767A1 (en) | 2016-06-24 | 2017-06-23 | Preparation of 212pb labeled monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3474904T3 true PL3474904T3 (pl) | 2024-12-16 |
Family
ID=56263569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17732126.2T PL3474904T3 (pl) | 2016-06-24 | 2017-06-23 | Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11306038B2 (pl) |
| EP (1) | EP3474904B1 (pl) |
| JP (1) | JP7176958B2 (pl) |
| CN (1) | CN109310789B (pl) |
| AU (1) | AU2017281649B2 (pl) |
| CA (1) | CA3026599A1 (pl) |
| ES (1) | ES2991349T3 (pl) |
| IL (1) | IL263808B2 (pl) |
| MX (1) | MX2018016121A (pl) |
| PL (1) | PL3474904T3 (pl) |
| WO (1) | WO2017220767A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| JP7544819B2 (ja) | 2019-12-05 | 2024-09-03 | サイエンコンス アクスイェ セルスカプ | 高度に精製された212Pbの製造 |
| IL310474A (en) | 2021-08-11 | 2024-03-01 | Nuclear Res And Consultancy Group | System and method of production and isolation of charged radionuclides |
| CN118715026A (zh) * | 2022-02-24 | 2024-09-27 | 阿尔法陶医疗有限公司 | 对流增强扩散性α-发射体辐射疗法 |
| JP7816003B2 (ja) * | 2022-06-06 | 2026-02-18 | Jfeエンジニアリング株式会社 | 放射性物質の標識方法 |
| US20240091705A1 (en) * | 2022-09-16 | 2024-03-21 | Viewpoint Molecular Targeting, Inc. | Removal of free-unlabeled cationic and anionic solution phase radionuclides from radiopharmaceuticals using solid-phase extraction techniques |
| WO2025163083A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recobminant dll3 binding proteins and their use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| DE10040771A1 (de) | 2000-08-21 | 2002-03-14 | Altmann Therapie Gmbh & Co Kg | Neue, 224Ra enthaltende, radiotherapeutisch wirksame Formulierungen und Verfahren zu ihrer Herstellung |
| DE10347459B3 (de) * | 2003-10-13 | 2005-05-25 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
| HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| WO2012032043A1 (en) | 2010-09-07 | 2012-03-15 | Areva Med Llc | 212 pb imaging |
| SG11201706849SA (en) | 2015-02-26 | 2017-09-28 | Sciencons AS | Radiopharmaceutical solutions with advantageous properties |
| NO3061464T3 (pl) * | 2015-02-26 | 2018-03-24 | ||
| US9433690B1 (en) * | 2015-02-26 | 2016-09-06 | Sciencons AS | Radiopharmaceutical solutions with advantageous properties |
-
2017
- 2017-06-23 IL IL263808A patent/IL263808B2/en unknown
- 2017-06-23 MX MX2018016121A patent/MX2018016121A/es unknown
- 2017-06-23 WO PCT/EP2017/065508 patent/WO2017220767A1/en not_active Ceased
- 2017-06-23 EP EP17732126.2A patent/EP3474904B1/en active Active
- 2017-06-23 ES ES17732126T patent/ES2991349T3/es active Active
- 2017-06-23 JP JP2018566836A patent/JP7176958B2/ja active Active
- 2017-06-23 CA CA3026599A patent/CA3026599A1/en active Pending
- 2017-06-23 AU AU2017281649A patent/AU2017281649B2/en active Active
- 2017-06-23 PL PL17732126.2T patent/PL3474904T3/pl unknown
- 2017-06-23 CN CN201780038560.8A patent/CN109310789B/zh active Active
- 2017-06-23 US US16/307,811 patent/US11306038B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7176958B2 (ja) | 2022-11-22 |
| EP3474904B1 (en) | 2024-08-07 |
| ES2991349T3 (es) | 2024-12-03 |
| IL263808B2 (en) | 2025-04-01 |
| NZ749058A (en) | 2025-07-25 |
| JP2019523232A (ja) | 2019-08-22 |
| AU2017281649A1 (en) | 2019-01-03 |
| EP3474904A1 (en) | 2019-05-01 |
| CN109310789A (zh) | 2019-02-05 |
| CN109310789B (zh) | 2021-12-03 |
| AU2017281649B2 (en) | 2023-07-27 |
| CA3026599A1 (en) | 2017-12-28 |
| MX2018016121A (es) | 2019-05-30 |
| US11306038B2 (en) | 2022-04-19 |
| US20190194087A1 (en) | 2019-06-27 |
| IL263808A (en) | 2019-02-03 |
| IL263808B1 (en) | 2024-12-01 |
| WO2017220767A1 (en) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| IL272274A (en) | B7-h4 antibodies and methods of use thereof | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| HUE060019T2 (hu) | Anti-LAG3 antitestek | |
| EP3532489A4 (en) | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| PL3474904T3 (pl) | Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| IL256097A (en) | Antibody epitope | |
| EP3507307A4 (en) | BISPECIFIC ANTIBODIES | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| DK3452513T3 (da) | Humaniserede anti-il-ir3-antistoffer | |
| DK3649152T3 (da) | ROR1-antistoffer | |
| HUE061076T2 (hu) | Humanizált anti-C1s ellenanyagok alkalmazási eljárások | |
| EP3532034A4 (en) | ANTI-APOE ANTIBODY | |
| EP3487518A4 (en) | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) |